Krystal Biotech reports first VYJUVEK revenue of $8.6M; net income $80.7M in Q3 2023

Krystal Biotech, Inc.

2023-Q3 EPS reported $0.08 revenue$8,556,000

VYJUVEK net product revenue $8.6M in Q3 2023; 284 Patient Start Forms from 136 prescribers; patient compliance 96%.
Net income $80.7M ($2.79 diluted EPS) vs net loss ($29.9M) year-ago; includes $100M gain on PRV sale.
Cash, equivalents and investments $598.6M; R&D expense $10.6M; SG&A $23.7M.
Pipeline: Cohort 1 complete in Phase 1 KB407 (CF); first patient dosed in Phase 1 KB707 (solid tumors); IND cleared for KB408 (AATD).
B-VEC filed for EU marketing authorization; Japan extension study dosed 5 patients; PRV sold for $100M; ASTRA facility operational.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Krystal Biotech, Inc. reported financial results for the quarter ending September 30, 2023.

Period: the quarter ending September 30, 2023
Result: reported results

Exact text from the filing

On November 6, 2023, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Krystal Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001711279-23-000074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.